---
created: 2025-04-13
updated: 2025-04-13T10:52
id: m2JoJk6?hH
specialty: neuro
specialty_id: 236
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::12-neuro-&-special-senses::06-pharm::11-neurodegenerative-disease-therapy
  - "source/ak-step1-v11:": 
  - theme/firstaid::12-neuro-&-special-senses::06-pharm::11-neurodegenerative-disease-therapy::als::riluzole
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::14-neuro::14-riluzole
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::15-other-neuro::riluzole
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::06-neuro/psych::fa-neuro
  - source/ak-step1-v11::^other::^highyield::1-highyield
  - source/ak-step1-v11::^systems::neuro::pharmacology
  - "source/ak-step2-v11:": 
  - theme/uworld::10000-99999::19000-19999::19670"
type: flashcard
---

# Question
**Riluzole** is a treatment for **ALS** that increases survival by decreasing **glutamate** excitotoxicity

---

# Answer
Therefore, higher extracellular magnesium levels block the NMDA channel, decreasing the influx of calcium and sodium to inhibit glutamate-mediated neuron depolarization.  This vicious cycle of depolarization (excitotoxicity) and glutamate release has been identified as a final common pathway of brain tissue loss (eg, ischemic stroke, traumatic brain injury, Alzheimer dementia).